1. miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma
- Author
-
Yanbing Li, Zhimin Huang, Zhihong Liao, Hai Li, Guohong Wei, Liehua Liu, Juan Liu, Xiaojie Lin, and Hongyu Guan
- Subjects
Pathology ,medicine.medical_specialty ,Oncogene ,endocrine system diseases ,Cell growth ,business.industry ,General Neuroscience ,Cell ,RAC1 ,General Medicine ,Articles ,Cell cycle ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,Thyroid carcinoma ,medicine.anatomical_structure ,microRNA ,medicine ,Cancer research ,General Pharmacology, Toxicology and Pharmaceutics ,business ,Thyroid cancer - Abstract
Accumulating evidence suggests that some microRNAs (miRNAs) are involved in papillary thyroid carcinoma (PTC) progression. However, it remains necessary to elucidate the underlying molecular mechanisms involved. In the present study, we investigated the role of microRNA-101 (miR-101) in PTC via targeting of Ras-related C3 botulinum toxin substrate 1 (Rac1). The results showed that miR-101 was significantly downregulated in PTC tissues compared with adjacent normal tissues. Restoration of miR-101 expression significantly inhibited cell proliferation in the K1 PTC cell line. Moreover, algorithm-based and experimental strategies verified Rac1 as a direct target of miR-101 in the K1 cell line. Taken together, these findings suggest that miR-101 inhibited PTC growth via the downregulation of Rac1 expression, providing a better understanding of miRNA-modulated signaling networks for future cancer therapeutics.
- Published
- 2013